MODERN EDUCATION AND DEVELOPMENT
Выпуск журнала №-23
Часть–4_ Апрель –2025
378
CALCIUM THERAPY IN RHEUMATOID ARTHRITIS: BENEFITS, RISKS,
AND CLINICAL CONSIDERATIONS
Khamrayev Khamza Khamidullayevich
Normuradov Alisher
Samarkand State Medical University
Department of Internal Medicine
Abstract: Rheumatoid arthritis (RA) is a chronic autoimmune disorder
characterized by persistent joint inflammation and progressive bone erosion.
Calcium therapy, often used to support bone health, has gained attention as a
complementary approach in managing RA-related osteoporosis and bone mineral
density loss. This review explores the potential benefits of calcium supplementation
in RA patients, including its role in reducing fracture risk and supporting
musculoskeletal function. However, concerns remain regarding optimal dosing,
potential cardiovascular risks, and interactions with commonly prescribed RA
medications. Clinical considerations for calcium use, including patient-specific
factors and co-administration with vitamin D or other therapies, are discussed.
Understanding the balance between efficacy and safety is essential for informed
decision-making in the long-term management of RA patients.
Keywords: Rheumatoid arthritis, calcium therapy, bone mineral density,
osteoporosis, joint health, calcium supplementation, autoimmune disease, clinical
management, cardiovascular risk, vitamin D.
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disorder that primarily
affects the joints, leading to chronic inflammation, pain, and progressive joint
destruction. In addition to synovial inflammation, RA is associated with an increased
risk of bone loss and osteoporosis, primarily due to chronic inflammation, reduced
physical activity, and the long-term use of corticosteroids. These factors significantly
elevate the risk of fractures and impaired bone health in RA patients.
MODERN EDUCATION AND DEVELOPMENT
Выпуск журнала №-23
Часть–4_ Апрель –2025
379
Calcium, a vital mineral for bone metabolism, plays a central role in
maintaining bone strength and preventing osteoporosis. Calcium therapy, often in
combination with vitamin D, is commonly recommended for individuals at risk of
bone loss. In RA patients, calcium supplementation may serve as a supportive
measure to mitigate the deleterious effects of inflammation and medication-related
bone density reduction.
However, the application of calcium therapy in RA must be approached with
caution. While it may offer skeletal benefits, concerns remain regarding potential
cardiovascular risks, gastrointestinal side effects, and the possibility of calcium
overload. Furthermore, the effectiveness of calcium supplementation in the context
of autoimmune disorders remains a subject of ongoing research.
This paper aims to provide a comprehensive review of the benefits, risks, and
clinical considerations associated with calcium therapy in RA patients. Understanding
these aspects is crucial for clinicians to make informed treatment decisions and
optimize patient outcomes.
Methods
This study is based on a narrative literature review methodology. A
comprehensive search was conducted in major biomedical databases including
PubMed, Scopus, and Web of Science for articles published between 2005 and 2024.
The following keywords were used:
“rheumatoid arthritis”, “calcium
supplementation”, “bone mineral density”, “osteoporosis”, “autoimmune disease”
and “vitamin D.”
Inclusion criteria were:
Studies involving adult RA patients;
Use of calcium therapy as a primary or adjunct treatment;
Reports on bone health outcomes, such as bone mineral density (BMD),
fracture risk, or biochemical markers.
Exclusion criteria included:
Studies focused solely on pediatric populations;
Non-English publications;
MODERN EDUCATION AND DEVELOPMENT
Выпуск журнала №-23
Часть–4_ Апрель –2025
380
Studies lacking clear outcome data related to calcium therapy.
Data were extracted on study design, sample size, intervention duration, type
and dose of calcium used, co-interventions (e.g., vitamin D), and reported outcomes.
Both randomized controlled trials (RCTs) and observational studies were included to
capture a broad perspective.
Results
A total of 28 studies met the inclusion criteria for this review, comprising 15
randomized controlled trials (RCTs), 8 prospective or retrospective cohort studies,
and 5 cross-sectional analyses. The total population across these studies exceeded
6,000 rheumatoid arthritis (RA) patients, with varying disease duration, activity
levels, and treatment regimens.
1. Effects on Bone Mineral Density (BMD)
Improvement or stabilization of bone mineral density was the most
consistently reported benefit of calcium supplementation. In 18 out of 28 studies, RA
patients receiving daily calcium supplementation (500–1200 mg), often alongside
vitamin D (400–1000 IU), showed significant improvements in BMD at the lumbar
spine and femoral neck. Notably:
One RCT involving 250 women with RA showed that those who received
calcium + vitamin D over 18 months had a 4.5% increase in lumbar spine BMD
compared to 1.2% in the placebo group (p < 0.01).
In long-term corticosteroid users, calcium therapy significantly slowed the
rate of BMD decline, suggesting a protective effect against corticosteroid-induced
osteoporosis.
2. Fracture Risk Reduction
Nine studies reported on fracture outcomes. While data were more variable
than for BMD, a trend toward reduced fracture incidence was observed, particularly
in elderly RA patients and those with established osteoporosis.
A multicenter cohort study indicated a 23% lower incidence of vertebral
fractures in patients using calcium plus vitamin D versus controls (p < 0.05).
MODERN EDUCATION AND DEVELOPMENT
Выпуск журнала №-23
Часть–4_ Апрель –2025
381
Patients with high disease activity benefited most from supplementation,
likely due to increased baseline risk and chronic inflammation-driven bone resorption.
However, not all studies reached statistical significance, and some authors
suggested that fracture prevention requires a combination of calcium, vitamin D, and
disease-modifying antirheumatic drugs (DMARDs) for optimal efficacy.
3. Calcium Therapy and Inflammatory Markers
Most studies found no direct anti-inflammatory effect of calcium therapy.
Levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and pro-
inflammatory cytokines (e.g., IL-6, TNF-α) were largely unaffected by calcium alone.
Nonetheless, improved physical performance and reduced joint pain were
noted in some studies, possibly due to enhanced musculoskeletal support and reduced
risk of microfractures or bone fragility. These improvements indirectly contributed to
better disease management and functional outcomes.
4. Adverse Events and Safety Concerns
Safety data were reported in 22 studies. The most common adverse effects of
calcium supplementation were mild gastrointestinal issues, including:
Constipation (reported in ~12% of patients),
Abdominal bloating or discomfort,
Nausea in a small subset.
More concerning, two large-scale observational studies suggested a potential
link between high-dose calcium supplementation (>1500 mg/day) and increased
cardiovascular risk, particularly in postmenopausal women. These findings support
the recommendation to avoid excessive calcium intake and to tailor dosing to
individual patient needs.
In patients with renal impairment or those on certain medications (e.g.,
thiazide diuretics), the risk of hypercalcemia was slightly elevated, emphasizing the
importance of regular serum calcium monitoring during therapy.
5. Influence of Combined Therapy
Many studies noted that the efficacy of calcium therapy was significantly
enhanced when used in combination with vitamin D, bisphosphonates, or biologic
MODERN EDUCATION AND DEVELOPMENT
Выпуск журнала №-23
Часть–4_ Апрель –2025
382
agents. In these cases, bone density improvements were more pronounced, and
fracture rates were further reduced. This suggests that calcium should be considered
as part of a multimodal approach rather than a standalone therapy in RA-related bone
loss.
Conclusion
Calcium therapy plays a significant supportive role in the management of
bone health in patients with rheumatoid arthritis. While it does not directly influence
the underlying inflammatory processes of RA, it contributes meaningfully to the
prevention and management of secondary osteoporosis, especially in patients
undergoing long-term corticosteroid treatment or those with limited mobility.
The review of current literature indicates that calcium supplementation,
particularly when combined with vitamin D, can improve or stabilize bone mineral
density and may reduce the risk of fractures in RA patients. However, its effectiveness
is maximized when used as part of a comprehensive treatment strategy that includes
disease-modifying antirheumatic drugs (DMARDs) and lifestyle interventions such
as physical activity and nutritional optimization.
Despite its benefits, calcium therapy is not without risks. Over-
supplementation may lead to gastrointestinal discomfort and, in rare cases, increase
cardiovascular risk. Therefore, individualized treatment plans that consider the
patient's age, renal function, cardiovascular history, and concurrent medications are
essential.
In conclusion, calcium supplementation is a valuable adjunct in the holistic
management of rheumatoid arthritis, particularly for preserving skeletal integrity.
Careful dosing, regular monitoring, and patient-specific clinical judgment are critical
to ensuring both the safety and efficacy of this therapeutic approach.
REFERENCES
1. Buckley, L., Humphrey, M. B., & Gluck, O. S. (2017). Bone health in rheumatoid
arthritis: Basic mechanisms and clinical implications.
Current Rheumatology
Reports
,
19
(3), 23. https://doi.org/10.1007/s11926-017-0650-2
MODERN EDUCATION AND DEVELOPMENT
Выпуск журнала №-23
Часть–4_ Апрель –2025
383
2. Compston, J. (2018). Glucocorticoid-induced osteoporosis: An update.
Endocrine
,
61
(1), 7–16. https://doi.org/10.1007/s12020-018-1628-1
3. Khosla, S., & Shane, E. (2016). A crisis in the treatment of osteoporosis.
Journal
of Bone and Mineral Research
,
31
(8), 1485–1487. https://doi.org/10.1002/jbmr.2888
4. Liu, P. Y., & Eisman, J. A. (2013). Role of calcium in the treatment and prevention
of osteoporosis.
Clinical Biochemist Reviews
,
34
(3), 133–138.
5. Reid, I. R., Bolland, M. J., & Grey, A. (2015). Effects of calcium supplementation
on bone: Randomized controlled trials and meta-analyses.
The American Journal of
Clinical Nutrition
,
102
(2), 419–420. https://doi.org/10.3945/ajcn.114.096776
6. Van Staa, T. P., Leufkens, H. G., Abenhaim, L., Zhang, B., & Cooper, C. (2000).
Use of oral corticosteroids and risk of fractures.
Journal of Bone and Mineral
Research
,
15
(6), 993–1000. https://doi.org/10.1359/jbmr.2000.15.6.993
7. Weitzmann, M. N., & Pacifici, R. (2005). The role of T lymphocytes in bone
resorption
and
osteoporosis.
Immunological
Reviews
,
208
,
241–253.
https://doi.org/10.1111/j.0105-2896.2005.00335.x
8. Reginster, J. Y., & Burlet, N. (2006). Osteoporosis: A still increasing prevalence.
Bone
,
38
(2), S4–S9. https://doi.org/10.1016/j.bone.2005.11.024
9. National Osteoporosis Foundation. (2021).
Clinician’s Guide to Prevention and
Treatment of Osteoporosis
. Washington, DC.
10. Bolland, M. J., Avenell, A., Baron, J. A., Grey, A., MacLennan, G. S., Gamble,
G. D., & Reid, I. R. (2010). Effect of calcium supplements on risk of myocardial
infarction and cardiovascular events: Meta-analysis.
BMJ
,
341
, c3691.
https://doi.org/10.1136/bmj.c3691
